BioSpace News Archive

The latest market analysis report published by Reports and Data, titled ‘Global WHIM Syndrome Treatment Market – Forecast to 2030,’ thoroughly examines the WHIM Syndrome Treatment industry to provide essential data & information for the targeted readers.

The latest market analysis report published by Reports and Data, titled ‘Global Wolman Disease Treatment Market – Forecast to 2030,’ thoroughly examines the Wolman Disease Treatment industry to provide essential data & information for the targeted readers.

The Amyloidosis Research Consortium announces the launch of ASPIRE: Amyloidosis Stakeholder Partnerships for Impact Reach and Equity, a collaborative of biotech and pharmaceutical companies committed to advancing solutions, improving diagnosis and systems of care, and addressing obstacles to health equity on behalf of amyloidosis patients.

While breast cancer death rates dropped by 43% from 1989 to 2020, Black women continue to be 40% more likely to die from the disease despite lower incidence.

Paradigm Biopharmaceuticals Ltd is pleased to announce that the primary endpoint has been met and additionally significant improvement in Western Ontario and McMaster Universities Osteoarthritis Index pain and function scores were demonstrated for injectable iPPS in the PARA_OA_008 phase 2 clinical trial.

Olympus, a global leader in designing and delivering innovative medical technology solutions, announced a new patient access program called Olympus UNITE that assists patients in gaining access to new medical technologies.

According to Vision Research Reports, the global gene panel market was surpassed at USD 750.8 million in 2021 and is expected to hit around USD 2.97 billion by 2030, growing at a CAGR of 16.51% from 2022 to 2030.

The global hyperthermia cancer treatment market size is expected to reach US$ 265 million by 2030 from US$ 160 million in 2020, growing at a CAGR of 5.8% from 2021 to 2030.

The forensic genomics market is anticipated to witness significant growth as the majority of companies aim to use customer databases in combination with cutting-edge sequencing technologies.

POXEL SA, a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic diseases, announces the publication of its half-year financial report as of June 30, 2022.